Mode
Text Size
Log in / Sign up

Higher Triglyceride-glucose index levels are associated with increased risk of Atrial FibrillationHigher Triglyceride-Glucose Index Linked to Increased Risk of Atrial Fibrillation

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that higher TyG index levels are associated with increased risk of Atrial Fibrillation in these populations.

This meta-analysis evaluated the association between the Triglyceride-glucose (TyG) index and Atrial Fibrillation across a sample size of 25,376 individuals. The study focused on identifying TyG index levels in patients with AF compared to non-AF individuals, primarily within Asian populations.

The meta-analysis found that TyG index levels were significantly higher in patients with Atrial Fibrillation (SMD: 0.65; 95% CI: 0.34 to 0.95; P < 0.001). The authors suggest the TyG index may serve as a promising biomarker for predicting new-onset AF, post-ablation recurrence, and postoperative AF. It holds potential application in clinical risk stratification and early prevention.

A primary limitation noted by the authors is that the generalizability of these findings to non-Asian populations requires further validation. Because the underlying data are observational, the results indicate an association rather than a causal relationship. The TyG index should not be considered a definitive diagnostic tool at this stage.

How this fits prior evidence

This finding addresses a gap in identifying metabolic biomarkers for Atrial Fibrillation risk stratification. While other evidence highlights physical factors like sarcopenia and procedural interventions such as catheter ablation or pulsed field ablation to manage AF, this meta-analysis provides a potential biochemical marker (TyG index) for early prevention and predicting recurrence after procedures.

Researchers analyzed data from over 25,000 individuals to look at the link between a specific blood measurement called the triglyceride-glucose (TyG) index and atrial fibrillation. This condition is an irregular and often rapid heart rate. The study found that people with atrial fibrillation had significantly higher TyG index levels compared to those without the condition.

The findings suggest that this index could potentially help doctors identify patients who might experience new cases of atrial fibrillation or those at risk for recurrence after a procedure called catheter ablation. Because it is an observational study, it shows a link between these factors rather than proving one causes the other.

It is important to note that most participants in this study were from Asian populations. More research is needed to see if these results apply equally to other groups. While the TyG index shows promise as a tool for early prevention and risk assessment, it is not currently a definitive diagnostic tool.

What this means for you:
Higher triglyceride-glucose levels are linked to atrial fibrillation risk, but more research is needed for all populations.

Common questions

What is the TyG index and how does it relate to heart health?

The triglyceride-glucose (TyG) index is a measurement used to assess risk. This study found that individuals with atrial fibrillation had significantly higher TyG levels than those without the condition. It may help doctors identify patients who need earlier prevention or closer monitoring for irregular heartbeats.

Can this test predict if my heart rhythm will stay steady after treatment?

The study suggests that the TyG index might be a useful tool for predicting several outcomes, including new-onset atrial fibrillation and the recurrence of the condition after catheter ablation. However, because this was an observational study, it shows a link rather than a guaranteed prediction.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedJul 2026
View Original Abstract ↓
Insulin resistance (IR) plays a pivotal role in the onset and progression of atrial fibrillation (AF). As a simple, reliable surrogate marker of IR, the triglyceride-glucose (TyG) index has drawn growing attention for its association with AF. This study aimed to comprehensively evaluate the strength of the association between the TyG index and AF, as well as its specific subtypes including new-onset AF, AF recurrence after catheter ablation, and postoperative AF, via a systematic review and meta-analysis. Relevant literature was systematically retrieved from PubMed, Web of Science, CNKI, Wanfang Data Knowledge Service Platform, and VIP Chinese Journal Database from their inception to September 30, 2025. Literature screening, data extraction and quality assessment (using the Newcastle-Ottawa Scale) were independently performed by two researchers. A random-effects model was adopted to calculate the pooled standardized mean difference (SMD) and odds ratio (OR) with 95% confidence intervals (CIs), so as to compare TyG index levels between AF and non-AF populations, and to assess the association of the TyG index (treated as both a continuous and categorical variable) with AF risk. Subgroup analysis, meta-regression and sensitivity analysis were conducted to explore sources of heterogeneity and verify the robustness of the results. A total of 19 observational studies were included, involving an overall sample of 25,376 participants. The meta-analysis yielded the following findings: ① Based on 15 studies, TyG index levels were significantly higher in AF patients than in non-AF individuals (SMD: 0.65; 95% CI: 0.34–0.95; I2 = 98%; P  Current evidence, predominantly derived from Asian populations, indicates a significant positive association between the TyG index and AF risk. The TyG index may serve as a promising potential biomarker for predicting new-onset AF, post-ablation AF recurrence and postoperative AF in this population. Its generalizability to non-Asian populations requires further validation. Nevertheless, with the advantages of convenient measurement and low cost, the TyG index holds broad application prospects in clinical risk stratification and early prevention of AF.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.